AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06231420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometer
Description: pedometer
Study NCT04285242 — intervention group
Intervention type: OTHER
Intervention: Observational assessments
Description: Clinical assessments
Study NCT05636189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming during induction of anesthesia
Description: Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
Study NCT05636189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prewarmed intravenous fluid administration
Description: Prewarmed intravenous fluid is connected.
Study NCT05119218 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT06388304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE Online PAT Program
Description: Online program: behavioral intervention based on Positive Affect Training (PAT)
Study NCT05040893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises).
Study NCT05553483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama plus acupoint stimulation by laser
Description: This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama ).
Study NCT05553483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupoint stimulation by laser
Description: This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
Study NCT05242757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed-activated Killer Immune Cells
Description: Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
Study NCT06186713 — intervention group
Intervention type: OTHER
Intervention: This was an observational study, and no Intervention was given to the patients.
Description: This was an observational study, and no Intervention was given to the patients.
Study NCT05971862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
Study NCT05490836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN α-2b; TAF
Description: TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
Study NCT05490836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG IFN α-2b; TAF
Description: TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
Study NCT05212506 — intervention group
Intervention type: BIOLOGICAL
Intervention: vaccinated and unvaccinated
Description: the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
Study NCT05916105 — intervention group
Intervention type: DRUG
Intervention: Ciprofloxacin Tablets
Description: Ciprofloxacin antibiotic
Study NCT05554796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic classic stapedotomy
Description: Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
Study NCT05554796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic reversal stapedotomy
Description: Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
Study NCT01422148 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amiodarone
Description: oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Study NCT01422148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Study NCT01422148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Study NCT06210477 — intervention group
Intervention type: DRUG
Intervention: medical treatment for lower urinary tract symptoms
Description: The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
Study NCT04935398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The aim is to test two treatment techniques against each other to see how effective they are.
Study NCT05317884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Email
Study NCT05339581 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
Study NCT05339581 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
Study NCT05339581 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate Capsule
Description: Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
Study NCT05339581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib Mesylate Capsule
Description: Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
Study NCT03708549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
Study NCT03708549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
Study NCT05040802 — intervention group
Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis
Study NCT06417359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh Fixation
Description: That mesh will be fixation with three tackers.
Study NCT06417359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Mesh Fixation
Description: That mesh will not be fixation
Study NCT05997862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFFS
Description: This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
Study NCT05924737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivatin
Description: 40 hours of continuous awakening
Study NCT05924737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep recovery
Description: sleep recovery after 40 hours of continuous awakening
Study NCT05515861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
Study NCT05893602 — intervention group
Intervention type: OTHER
Intervention: Blood sample analysis
Description: Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
Study NCT04903925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impacted tooth extraction
Description: All patients will undergo a surgical tooth extraction
Study NCT04903925 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Impacted tooth extraction
Description: All patients will undergo a surgical tooth extraction
Study NCT04982757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
Study NCT04982757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
Study NCT05512793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique First colonoscopy without PolyDeep
Description: Standard technique First colonoscopy without PolyDeep
Study NCT05512793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Combination technique First colonoscopy with PolyDeep
Description: Combination technique First colonoscopy with PolyDeep
Study NCT06335810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Intervention
Description: Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.
Study NCT06335810 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Individual Lifestyle Intervention
Description: The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.
Study NCT06335810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social Network Member
Description: The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
Study NCT05103722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise Training
Description: Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
Study NCT05701202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super-Whey protein
Description: 2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
Study NCT05701202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isonitrogenous whey protein
Description: 2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
Study NCT04800653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
Study NCT05198804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 will be administered.
Study NCT05198804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study NCT05524688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan
Description: 2, 250 mg capsules of beta-glucan per day
Study NCT05524688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2, 250 mg capsules of cellulose
Study NCT05969197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Match Play Training
Description: 15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
Study NCT05969197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: 15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
Study NCT06396520 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational
Description: No intervention, observational
Study NCT05345132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 20 Mg
Description: The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
Study NCT05345132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
Study NCT05991271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus-Vitae Transcatheter Heart Valve System
Description: The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
Study NCT04818372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313-Dose escalation
Description: Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
Study NCT04818372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313
Description: Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
Study NCT04818372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Study NCT04818372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg/day lenalidomide 21 of 28 days cycle
Study NCT05570669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose
Description: Taking the colonoscopy preparation drug (Clensia) in a single administration
Study NCT05570669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose
Description: Taking the colonoscopy preparation drug (Clensia) in two stages of administration
Study NCT06490341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP Regimen, Nimotuzumab, Sintilimab
Description: gemcitabine,ciplatin, nimotuzumab, sintilimab
Study NCT05897021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing on Minority Stressors
Description: The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
Study NCT05897021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Writing
Description: To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.